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Abstract
Objectives The 8th International Forum for Liver Magnetic Resonance Imaging (MRI), held in Basel, Switzerland, in October
2017, brought together clinical and academic radiologists from around the world to discuss developments in and reach consensus
on key issues in the field of gadoxetic acid–enhanced liver MRI since the previous Forum held in 2013.
Methods Twomain themes in liverMRIwere considered in detail at the Forum: the use of gadoxetic acid for contrast-enhancedMRI
in patients with liver cirrhosis and the technical performance of gadoxetic acid–enhanced liver MRI, both opportunities and chal-
lenges. This article summarises the expert presentations and the delegate voting on consensus statements discussed at the Forum.
Results and conclusions It was concluded that gadoxetic acid–enhanced MRI has higher sensitivity for the diagnosis of hepa-
tocellular carcinoma (HCC), when compared with multidetector CT, by utilising features of hyperenhancement in the arterial
phase and hypointensity in the hepatobiliary phase (HBP). Recent HCC management guidelines recognise an increasing role for
gadoxetic acid–enhanced MRI in early diagnosis and monitoring post-resection. Additional research is needed to define the role
of HBP in predicting microvascular invasion, to better define washout during the transitional phase in gadoxetic acid–enhanced
MRI for HCC diagnosis, and to reduce the artefacts encountered in the arterial phase. Technical developments are being directed
to shortening the MRI protocol for reducing time and patient discomfort and toward utilising faster imaging and non-Cartesian
free-breathing approaches that have the potential to improve multiphasic dynamic imaging.
Key Points
• Gadoxetic acid–enhanced MRI provides higher diagnostic sensitivity than CT for diagnosing HCC.
• Gadoxetic acid–enhanced MRI has roles in early-HCC diagnosis and monitoring post-resection response.
• Faster imaging and free-breathing approaches have potential to improve multiphasic dynamic imaging.
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AASLD American Association for the
Study of Liver Diseases
AP Arterial phase
APASL Asian Pacific Association for the
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APHE Arterial phase hyperenhancement
BCLC Barcelona Clinic Liver Cancer
BW Body weight
CT Computed tomography
DN Dysplastic nodule
DP Delayed phase
DWI Diffusion-weighted imaging
EASL-EORTC European Association for Study
of Liver-European Organisation
for Research and Treatment of Cancer
ECCM Extracellular contrast media
EOB Gadoxetic acid
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GD Gadolinium
Gd-EOB-DTPA Gadoxetic acid
HBP Hepatobiliary phase
HCC Hepatocellular carcinoma
HGDN High-grade dysplastic nodule
KLCSG-NCC Korean Liver Cancer Study Group
LCSGJ Liver Cancer Study Group of Japan
LI-RADS Liver Imaging Reporting
and Data System
MRI Magnetic resonance imaging
PVP Portal venous phase
RFA Radiofrequency ablation
T2W T2-weighted
TP Transitional phase
TRICKS Time-resolved imaging of
contrast kinetics
TSM Transient severe motion
TWIST Time-resolved angiography
with stochastic trajectories
US Ultrasound
WO Washout
Introduction
The 8th International Forum for Liver Magnetic Resonance
Imaging (MRI) was held in October 2017 in Basel,
Switzerland, and attended by 119 radiologists from Asia
(n = 46), Australia (n = 4), Europe (n = 48), North America
(n = 20), and South America (n = 1). Delegates were invited
to attend who had knowledge of MRI of the liver, including
the use of gadoxetic acid. Two main themes were explored at
the Forum: (1) the applications of gadoxetic acid (Primovist®,
Eovist®) for contrast-enhanced MRI in patients with liver
cirrhosis and (2) the technical performance of gadoxetic
acid–enhanced liver MRI, including opportunities and chal-
lenges. As in previous Forums [1–7], consensus statements on
selected topics were proposed based on the available evidence
and the expert opinions of participants. The final consensus
statements and the voting by delegates are presented in this
article. The online supplement includes additional information
on delegates’ views on current practice in liver MRI, based on
a questionnaire that was circulated pre-meeting.
Use of gadoxetic acid in patients with liver
cirrhosis
Washout in the transitional phase
The 2017-dated Liver Imaging Reporting and Data System
(LI-RADS), updated in 2018 [8, 9], defines washout ap-
pearance on contrast-enhanced MRI as a visually assessed
temporal reduction in the enhancement in tumour relative
to the composite liver tissue, resulting in extracellular
phase hypoenhancement. In other words, following initial
enhancement in the arterial phase (AP, sometimes referred
to as “washin”), “washout” is the relative hypointensity of
the observation compared with background liver tissue.
With extracel lular contrast media (ECCM), this
hypoenhancement can be assessed either in the portal ve-
nous phase (PVP) or the delayed phase (sometimes re-
ferred to as the “equilibrium” phase and obtained at about
3 min) or both. For gadoxetic acid, the hypoenhancement
must be assessed only in the PVP; hypointensity in the
transitional phase (TP) of gadoxetic acid—equivalent in
post-injection time to the delayed phase of ECCM—does
not qualify as washout. The theoretical rationale for this is
that lesion hypointensity in the TP could be due to one (or
both) of two things: true washout, or simply the increasing
enhancement of the surrounding liver from intra-
hepatocellular contrast uptake [10–13] (Fig. 1).
In contrast to LI-RADS v2018, which restricts the inter-
pretation of washout to the PVP only in order to maintain
high specificity [9], the Korean Liver Cancer Study Group
(KLCSG-NCC) guidelines v2014 allow identification of
washout in the PVP or the TP [14], and the Liver Cancer
Study Group of Japan (LCSGJ) v2014 permits identifica-
tion of washout in the PVP, TP, and even in the
hepatobiliary phase (HBP) of gadoxetic acid [15]. The ap-
proach advocated by these Asian guidelines increases the
sensitivity but decreases the specificity of the diagnosis of
HCC (see below). It can also lead to incorrect interpreta-
tion of so-called pseudo-washout in non-hepatocyte-
containing lesions (e.g. high-flow haemangiomas and
hypervascular cholangiocarcinomas).
Four retrospective studies from South Korea assessed
the specificity and sensitivity of lesion washout during
the PVP alone (defined as 50–60 s after gadoxetic acid
injection) or in combination with hypointensity in the TP
(3 min after gadoxetic acid injection) for diagnosing HCC
[16–19]. Washout in the PVP provided high specificity for
diagnosis of HCC in patients with chronic liver disease,
while washout in the PVP combined with hypointensity
in the TP lowered the specificity (from 97.9 to 86.3%
[18]), 92.9 to 78.6% [19], and 100 to 94.9% [17]). In con-
trast, the sensitivity for the detection of HCC increased
when washout in the PVP was combined wi th
hypointensity in the TP (from 70.9 to 86.6%, 66.7 to
72.9%, and 63.6 to 76.6%, respectively). At the time of
the Liver Forum, no published data were identified on al-
ternative timings of hypointensity assessment in the TP,
e.g. 2 min after injection, and no study had been reported
on the changes in specificity and sensitivity of diagnosis in
the context of LI-RADS criteria, i.e. after excluding LR-1
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(definitely benign), LR-2 (probably benign), and LR-M
(probably or definitely malignant but not HCC-specific).
Subsequently published studies have emphasised the in-
creased sensitivity with limited loss of specificity if
hypointensity on the HBP is included for diagnosing HCC
[20–23].
Consensus statement 1 To maximise specificity for HCC di-
agnosis using gadoxetic acid–enhanced MRI in patients with
cirrhosis or other risk factors and based on the current litera-
ture, “washout” of gadoxetic acid should be assessed only in
the PVP and not in the 3-min TP. [72/78 (92.3%) agreement]
Consensus statement 2 Further research is needed to under-
stand the TP using gadoxetic acid. In particular, research is
needed to define the physiological beginning and end of the
TP based on imaging features rather than fixed time points.
Relevant imaging features are likely to include the relative
signal intensity of liver parenchyma in comparison to
intrahepatic vessels. [81/88 (92.1%) agreement]
Consensus statement 3 Further research is needed to define
when post-AP hypointensity can no longer be interpreted as
“washout” with gadoxetic acid–enhanced MRI. Because the
temporal signal intensity of gadoxetic acid–enhancedMRI varies
across individuals, imaging features (as informed by Consensus
statement 2) should be used in this definition, if possible, instead
of fixed time points. [81/88 (92.1%) agreement]
Specificity of the hepatobiliary phase to diagnose
HCC
Kim et al [24] reported that the detection sensitivity for
high-grade dysplastic nodules (HGDN), early HCC, and
progressed HCC was significantly higher with gadoxetic
acid–enhanced MRI than with multidetector computed to-
mography (CT). Most HGDNs (82.4%) and early HCCs
(76.2%) demonstrated hypointensity on HBP images.
Hyperenhancement in the AP and washout are described
as the most specific imaging features for the diagnosis of
HCC in gadoxetic acid–enhanced MRI [25]. Bartolozzi
et al reported that lesion enhancement on vascular dynamic
and HBP imaging significantly correlated with the histo-
logical diagnosis of HCC (p < 0.0001) [25]. Golfieri et al
found that HBP hypointensity by itself was the strongest
MRI marker of malignancy in atypical cirrhotic nodules in
gadoxetic acid–enhanced MRI; HBP hypointensity alone
had 88% sensitivity, 97% specificity, 91% negative predic-
tive value, and 93% diagnostic accuracy, significantly su-
perior to any other MRI feature alone or combined [26].
Yoon et al described in a retrospective study of gadoxetic
acid–enhanced MRI that a significant proportion of non-
hypervascular HBP hypointense nodules (≥ 1 cm in diam-
eter) in patients with cirrhosis showed malignant features
on pathology (73.1%) [27]. In another group of patients
whose hypointense HBP nodules were followed up for at
least 12 months (mean 19 ± 10 months), 32.7% of nodules
developed hypervascularity and 78.8% showed at least one
imaging feature considered to indicate malignant change
[27]. However, hypointensity in the HBP by itself cannot
differentiate HGDN from early or progressed HCC.
Recommendations on terminology for nodules without AP
hyperenhancement and with HBP hypointensity in chronic
liver disease have subsequently been published by Motosugi
et al on behalf of the LI-RADS HBAWorking Group [28].
Consensus statement 4 Hypointensity in the HBP of
gadoxetic acid–enhanced MRI is the most sensitive
Fig. 1 Hypoenhancement of
tumour tissue relative to liver:
defined as washout (WO) in the
portal venous phase (PVP) or
delayed phase (DP) with ECCM,
but as washout in the PVP
alone—not the transitional phase
(TP)—with gadoxetic acid. AP,
arterial phase; ECCM,
extracellular contrast medium
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imaging feature for the diagnosis of an HGDN, an early
HCC, or a progressed HCC in a patient at risk for HCC.
Notes: (1) This statement applies regardless of vascularity
in the AP; (2) hypointensity by itself has other potential
diagnoses (e.g. haemangiomas), besides HCC. [74/89
(83.2%) agreement]
Consensus statement 5Using multiparametric MRI (includ-
ing T2-weighted [T2W] and diffusion-weighted imaging
[DWI]), high specificity (> 90%) for the diagnosis of
HCC can be achieved when hypointensity in the HBP is
associated with solid arterial enhancement, regardless of
venous washout, in patients with liver cirrhosis. Note: A
small percentage of such lesions may represent other enti-
ties, e.g. cholangiocarcinoma or combined HCC-cholan-
giocarcinoma, while cysts and haemangiomas can be ruled
out by the signal in T2W and DWI sequences. [74/87
(85.1%) agreement]
Consensus statement 6 As a significant number of
hypovascular nodules (> 1 cm) that are hypointense on HBP
are, or eventually become (by 6–12 months), HCC in patients
with liver cirrhosis, close observation or intervention is rec-
ommended. Note: The current statement reflects practice dif-
ferences around the world, including the availability of sur-
gery, ablation, and biopsy. [80/88 (90.9%) agreement]
Detection of venous invasion with gadoxetic
acid–enhanced MRI
Macrovascular invasion is a characteristic feature of advanced
HCC, indicating high risk for metastasis, recurrence, liver
functional impairment, and poor prognosis (Barcelona Clinic
Liver Cancer [BCLC] stage C) [29].Microvascular invasion is
increasingly recognised as a risk factor for intrahepatic metas-
tases in BCLC stage B/A HCC patients, and even stage 0
HCC patients [30, 31].
Certain imaging features on gadoxetic acid–enhanced
MRI in the HBP have been shown in retrospective studies
to be predictive for microvascular invasion with high
specificity, including the presence and degree of
peritumoural hypointensity [13, 32, 33], peritumoural-
decreased uptake area [33], and an irregular and non-
smoo th tumour marg in [34 ] . The p re sence o f
intratumoural fat correlated negatively with microvascular
invasion, suggesting intratumoural fat may indicate a low-
er risk for microvascular invasion [35]. However, these
findings need confirmation in independent studies.
Consensus statement 7 In HCC patients, retrospective
single-centre studies suggest that peritumoural HBP
hypointensity may predict the presence of microvascular
invasion. Prospective multicentre studies are needed to
validate peritumoural HBP phase hypointensity for
predicting microvascular invasion in HCC, especially in
those with HCC < 2 cm. [39/43 (90.7%) agreement]
Differential diagnosis of HCC
The key imaging findings of HCC (1–2 cm) in LI-RADS
v2018 are arterial phase hyperenhancement (APHE,
washin), PVP or delayed phase washout, capsular appear-
ance, and threshold growth [8]. These criteria are based on
dynamic CT or on MRI with either ECCM (PVP or delayed
washout) or gadoxetic acid (PVP washout only) [8].
ECCM and gadoxetic acid are both gadolinium-based con-
trast agents, but they are not interchangeable because of the
differences in pharmacokinetics, dosage, and mechanism
of action [36].
Two meta-analyses showed superior sensitivity and pos-
itive predictive value (PPV) or negative likelihood ratio for
gadoxetic acid–enhanced MRI compared with CT for HCC
detection [37, 38]. One of the meta-analyses reported
equivalent sensitivity of gadoxetic acid and ECCM for
HCC detection [38]. However, gadoxetic acid–enhanced
MRI, compared with CT and ECCM-based MRI, may pro-
vide alternative imaging features that help differentiate
classic HCC from non-HCC malignant lesions. One of
the most important features of gadoxetic acid–enhanced
MRI is the ta rge to id HBP pat te rn— i . e . cen t ra l
hyperintensity with peripheral hypointensity in the rim in
the HBP—which can assist to differentiate non-HCC ma-
lignant lesions (combined HCC-cholangiocarcinoma,
intrahepatic cholangiocarcinoma) from HCC; see
Consensus statement 9 [8, 39–41].
Consensus statement 8 There is enough evidence (level 2) to
recommend gadoxetic acid–enhanced MRI over contrast-
enhanced CT as the primary imaging modality for imaging
HCC worldwide. There is not enough evidence currently to
support a similar statement comparing gadoxetic acid–
enhanced MRI against MRI using ECCM. [60/72 (83.3%)
agreement]
Consensus statement 9 Compared with CT or ECCM-based
MRI, gadoxetic acid–enhanced MRI may provide alterna-
tive imaging features that help in differentiating classic
HCC from non-HCC malignant lesions (combined HCC-
cholangiocarcinoma, intrahepatic cholangiocarcinoma).
One of the most important such features is the targetoid
HBP pattern, which increases the likelihood of a non-
HCC malignancy and by itself suffices for assigning an
LR-M category using LI-RADS. Notes: (1) Due to fibrous
or desmoplastic components, the targetoid pattern can be
seen in some HCC and rare benign lesions, e.g. sclerosed
haemangiomas; (2) combined tumours and small
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cholangiocarcinomas may overlap in imaging appearance
and can be difficult to differentiate from HCC. [66/83
(79.5%) agreement]
Consensus statement 10 Comparative studies have demon-
strated that gadoxetic acid–enhanced MRI provides higher
sensitivity with similar specificity for detecting malignancy
when compared with contrast-enhanced CT in cirrhotic liver.
Prospective studies are needed to compare the diagnostic per-
formance of gadoxetic acid–enhanced MRI with ECCM. [67/
83 (80.7%) agreement]
Capsule appearance in HCC with gadoxetic
acid–enhanced MRI
An enhancing “capsule” belongs to the major features of
HCC in the LI-RADS v2018 guidelines, where it is de-
fined as a peripheral rim of smooth hyperenhancement in
the PVP, DP, or TP [8]. The conventional capsule appear-
ance is a useful feature for diagnosing HCC [42] that has
been investigated in a comparative study of gadoxetic
acid and gadobenate dimeglumine [43]. However, the
capsule appearance may be obscured by the rapid disap-
pearance of contrast medium from the blood pool and by
hyperenhancement of the background liver on gadoxetic
acid–enhanced MRI, which are associated with inconsis-
tent sensitivities reported to range from around 20 to 90%
[44–47].
A hypointense rim on the HBP phase is considered an
ancillary feature in the LI-RADS v2018 guidelines and has
the potential to improve detection of the capsule, favouring the
diagnosis of HCC in addition to the conventional capsule
appearance alone.
Incorporating the assessment of a hypointense rim in
the HBP phase significantly improves the sensitivity and
accuracy for the detection of a histological capsule com-
pared with conventional capsule assessment (81.5 vs.
57.8% and 76.1 vs. 59.4%, respectively; p < 0.001)
[48]. Combined assessment of the HCC capsule using
the conventional technique and the hypointense rim dur-
ing the HBP can significantly improve the sensitivity
and accuracy for the diagnosis of HCC compared with
conventional capsule assessment alone (83.0 vs. 72.7%
and 84.1 vs. 75.1%, respectively; p < 0.001), with the
same specificity (91.5%) [48].
Consensus statement 11 The conventional capsule appear-
ance, a major feature in LI-RADS, may be obscured by the
rapid disappearance of contrast medium from the blood pool
when using ECCM or gadoxetic acid and progressive
hyperenhancement of the background liver on gadoxetic
acid–enhanced MRI, resulting in inconsistent sensitivities.
[73/82 (89.0%) agreement]
Consensus statement 12 A smooth hypointense rim on the
HBP phase, currently considered an ancillary feature in LI-
RADS, may have the potential to be included as a capsule
appearance. [66/83 (79.5%) agreement]
Detection of HCC foci prior to therapy decisions
Curative treatment options—including resection, liver trans-
plantation, and locoregional therapy such as radiofrequency
ablation (RFA)—are applicable only for early-stage HCC
conforming to the Milan Criteria [49, 50]. Precise staging is
therefore key to the optimal management of HCC.
In the more recent versions of management guidelines,
there has been an increasing role for hepatobiliary contrast-
enhanced MRI, greater use of follow-up imaging instead of
biopsy, and recommendation for a single dynamic study (ei-
ther CT or MRI) rather than two dynamic imaging modalities
for the diagnosis of small-diameter (< 2 cm) HCC [8, 51, 52].
For example, in the Asian Pacific Association for the Study of
the Liver (APASL) guideline [52], the diagnostic algorithm is
based on dynamic patterns and gadoxetic acid–enhancedMRI
is included as a first-line diagnostic tool for HCC (Fig. 2).
Geographical differences exist between guidelines, driven
largely by differences in treatment practices. In North America
and Europe, the greatest concern is for high specificity. Since
patients with a diagnosis of HCC may undergo liver transplan-
tation based on imaging criteria alone, stringent diagnostic
criteria are used to avoid false-positive HCC diagnoses [8, 29].
In the European Association for Study of Liver-European
Organisation for Research and Treatment of Cancer (EASL-
EORTC) guidelines, the radiological hallmark for HCC is
APHE and portal venous/delayed phase washout [29]. In the
2017 American Association for the Study of Liver Diseases
(AASLD) guidelines, MRI with ECCM or gadoxetic acid is
concluded to provide higher pooled sensitivity and similar spec-
ificity compared with CT [51]. However, the AASLD still rec-
ommends diagnostic evaluation of HCC with eithermultiphasic
CTormultiphasicMRI because they assume a similar diagnostic
performance. While this statement is strongly endorsed by the
AASLD guidelines, the supportive evidence level for CT is rel-
atively low. There are no randomised, controlled trials compar-
ing CT, ECCM-enhanced MRI, and gadoxetic acid–enhanced
MRI for the diagnosis of HCC in cirrhotic patients.
In contrast to the approach in North America and Europe, in
Asia, the primary aim is to maximise the sensitivity of HCC
diagnosis. This is justified by the greater use of locoregional
ablative therapies in Asia such as percutaneous ethanol injection,
RFA, and transarterial chemoembolisation. In the APASL guide-
lines, gadoxetic acid–enhanced MRI is preferred over ECCM-
enhanced MRI as a first-line diagnostic test. Hypointensity on
HBP imaging can replace washout on ECCM MRI. Typical
HCC can be diagnosed by imaging, regardless of its size, by
applying the “washin/washout criteria” [52].
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A recent meta-analysis concluded that CT and ECCM-
based MRI show similar diagnostic performance for detecting
HCC, while gadoxetic acid–enhanced MRI has the highest
overall sensitivity and PPV and may be the optimal single
method for diagnosis of HCC [37]. Another meta-analysis
concluded that MRI with an ECCM or gadoxetic acid has a
significantly higher sensitivity (82% vs. 66%) and lower neg-
ative likelihood ratio (0.20 vs. 0.37) versus CT, with no dif-
ferences between the techniques in specificities and positive
likelihood ratios [38].
A retrospective comparison against dynamic CT for staging
HCC reported that gadoxetic acid–enhanced MRI provided sig-
nificantly greater sensitivity (90.6% vs. 79.5%; p < 0.0001) and
more accurate BCLC staging (92.8% vs. 80.5%; p < 0.0001).
BCLC stage was correctly changed after gadoxetic acid–
enhanced MRI in 13.8% patients [53]. Gadoxetic acid–
enhancedMRIwas also superior to CT for detecting intrahepatic
recurrence post-curative surgery in patients with HCC. In a
lesion-by-lesion analysis, the sensitivity was significantly higher
for gadoxetic acid–enhanced MRI than on multidetector CT
(p < 0.005, both study reviewers) [54].
Consensus statement 13 Gadoxetic acid–enhanced MRI is an
accurate method for the diagnosis and staging of HCC (level 2
evidence in meta-analyses). Although the reported accuracy of
gadoxetic acid–enhanced MRI for diagnosis of HCC compares
favourably with that of CTor ECCM-enhancedMRI, the quality
of the evidence is still insufficient to recommend gadoxetic acid–
enhanced MRI over CT or ECCM-enhanced MRI in all patient
populations.Notes: (1) The statement “in all patient populations”
relates to different management patterns in different regions and
aims to capture differences in Western versus Asian treatment
practices (mentioned above). (2) “Gadoxetic acid–enhanced
MRI” refers to the entire package of imaging and not simply to
the HBP. [65/87 (74.7%) agreement]
Consensus statement 14 Gadoxetic acid–enhanced MRI is
useful for the preoperative staging of HCC, and also for
follow-up after surgery of HCC, as it can detect new lesions
with high sensitivity. [82/88 (93.2%) agreement]
Technical-related issues
Artefacts in the arterial phase
Arterial phase (AP) imaging is an essential component in
gadoxetic acid–enhanced MRI for making an HCC diagnosis
and monitoring treatment response, identifying AP
hyperenhancing benign lesions and liver metastases, and
assessing hepatic artery anatomy. Artefacts have been described
in the literature that may influence image quality in the AP.
Fig. 2 Asian Pacific Association
for the Study of the Liver
(APASL) Guidelines 2017 [52].
From Omata M, et al Hepatol Int.
11:317–370, with permission.
aCavernous haemangioma
sometimes shows hypointensity
on the equilibrium (transitional)
phase of dynamic Gd-EOB-
DTPA MRI (pseudo-washout). It
should be excluded by further
MRI sequences and/or other
imaging modalities. bCavernous
haemangioma usually shows
hypointensity on the hepatobiliary
phase of Gd-EOB-DTPA MRI. It
should be excluded by other MRI
sequences and/or other imaging
modalities. CT, computed
tomography; DN, dysplastic
nodule; Gd-EOB-DTPA,
gadoxetic acid; HCC,
hepatocellular carcinoma; MRI,
magnetic resonance imaging; US,
ultrasound
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The first description of “acute transient dyspnoea” after
administration of gadoxetic acid was published in 2013 [55].
In this single-centre prospective, nonrandomised observation-
al study, 198 patients underwentMRI of the abdomen (99with
gadoxetic acid, 99 with gadobenate dimeglumine). A propor-
tion of patients—14% in the gadoxetic acid and 5% in the
gadobenate dimeglumine group (p = 0.05)—described a tem-
porary, self-limiting phenomenon lasting for 10–20 s, during
which they felt as if they “couldn’t catch their breath”.
Concomitantly, there were cases of image quality being se-
verely degraded by patient respiratory motion during the AP,
which were more frequent in the gadoxetic acid than in the
gadobenate dimeglumine group, both for all patients (17 vs.
2%, p = 0.0007) and for the cirrhotic subpopulation (19 vs.
3%, p = 0.02). This effect did not extend to PVP, transitional
phase, or HBP.
A follow-up retrospective study by the same group [56] on
180 patients who underwent gadoxetic acid– and gadobenate
dimeglumine–enhanced MRI at different times reported a
higher incidence of respiratory motion-related artefact in the
AP (transient severe motion [TSM] artefact) associated with
gadoxetic acid than gadobenate (39% vs. 10%, p < 0.0001;
severe in 18% vs. 2%, respectively, p < 0.0001).
In a recent review of the published literature, the prevalence
of TSM associated with gadoxetic acid–enhanced MRI of the
liver ranged from 5 to 22% [57]. There are major geographical
differences in the prevalence of TSM, with higher rates in
patients in the USA compared with those in Asia [58].
The mechanism underlying TSM is unclear. Reported risk
factors for TSM in gadoxetic acid–enhanced MRI have in-
cluded male sex, high body mass index, breath-hold failure
[58, 59], presence of chronic obstructive pulmonary disease
[59], higher (off-label) gadoxetic acid injection doses [59],
and history of prior TSM [60, 61].
Proposed solutions to TSM are also widely debated, with-
out current consensus [53–69]. In a recent prospective obser-
vational study in 250 consecutive patients, the incidence of
acute transient dyspnoea after gadoxetic acid administration
was reported in less than 1% and combination with a
multiarterial phase technique significantly reduced the inci-
dence of artefacts [62].
Consensus statement 15 Gadoxetic acid–enhanced MRI has
been associated in the literature with artefacts during the AP
that are suspected to be secondary to TSM, as recently de-
scribed. TSM has an estimated prevalence of 2–39% (mean
15%). The mechanism of TSM is unclear. [71/76 (93.4%)
agreement]
Consensus statement 16 Several possible solutions have been
suggested to minimise the artefact of TSM. These include the
use of multiple APs, shortening the acquisition, use of
Cartesian and non-Cartesian free-breathing acquisition, con-
trast dilution, and changes in timingmethods. Further research
and a consensus are needed to determine which method
should be proposed to decrease/eliminate this artefact. [87/
89 (97.8%) agreement]
Shortened MRI protocols
A major objective in protocol optimisation is to provide high-
quality images within as short a time as possible. Discussion
of the optimal protocol for gadoxetic acid–enhancedMRI was
included in the First Liver Forum Consensus Manuscript
11 years ago [1]. In the “traditional” protocol (Fig. 3), non-
contrast sequences are acquired before gadoxetic acid injec-
tion, followed by dynamic evaluation. After a wait of 10 min
in patients with normal liver function and 20 min in patients
with liver cirrhosis or otherwise compromised liver function,
the HBP images are acquired. The total protocol duration is
approximately 35–40 min.
In an alternative “optimised” protocol using gadoxetic acid
(Fig. 4), pre-contrast T2W and DWI are moved before the
HBP. This can save 5 or even 8 min in the protocol. The time
saved using the optimised protocol can represent a decrease in
patient discomfort and costs relative to the traditional protocol
or provide an opportunity to perform optional additional
acquisitions.
Fig. 3 Traditional MRI protocol using gadoxetic acid—T1W, T2W, and DWI are performed before gadoxetic acid administration. DWI, diffusion-
weighted imaging
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Studies have demonstrated that if T2Wand DW images are
acquired after gadoxetic acid injection in the optimised proto-
col, the same results and comparable diagnostic capability are
obtained as in the “traditional” protocol [63, 64]. An exception
to the recommendation to use the optimised protocol is
suspected haemangioma, where it is suggested to perform
T2 and DWI before gadoxetic acid injection due to the high
specificity of T2W MRI in this situation [65, 66]. The results
can inform whether there is subsequently a need to inject
gadoxetic acid. Moreover, a T2W-basedMR cholangiography
cannot be performed after gadoxetic acid injection, unless it is
acquired within 5 min after gadoxetic acid injection.
Additional steps to consider when using an optimised MRI
protocol include (1) using bolus timing techniques for optimal
enhancement during the dynamic phase [67] and (2) starting
the HBP at about 10 min post-injection to save examination
time. Although a 20-min delay can improve the signal inten-
sity and liver-to-lesion contrast with benefit in some situa-
tions, about a 10-min delay is sufficient in most patients with-
out chronic liver disease [68]. (3) High flip angle delayed HBP
imaging is a useful adjunct to standard-enhanced MRI of the
liver. It allows for better sensitivity in focal liver detection,
particularly for small lesions, and this technique increases
the conspicuity of the biliary system, which is an additional
benefit of delayed imaging [69–71].
Consensus statement 17 The minimum protocol in the
cirrhotic/high-risk HCC-patient for screening and pre-
surgical evaluation/staging incudes:
& T1W in-phase and out-of-phase
& Pre-contrast plus dynamic contrast-enhanced evaluation
& T2W and DWI acquisition
& HBP at 20 min
& Optional additional sequences can be used for specific
clinical situations or according to institutional preference
[71/83 (85.5%) agreement]
Consensus statement 18 The minimum protocol in the non-
cirrhotic oncological patient (pre- and post-treatment) consists
of:
& T1W in-phase and out-of-phase
& Pre- and post-contrast contrast-enhanced dynamic
evaluation
a
b
Fig. 4 Optimised MRI protocol using gadoxetic acid. DWI, diffusion-weighted imaging
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& T2W and DWI acquisition
& HBP at 10–15 min
& Optional additional sequences can be used for specific
clinical situations or according to institutional preference
& Notes: In biliary-related diseases, perform T2 (and DWI)
and MR cholangiography before contrast administration.
Prospective studies are needed to see if the HBP alone
may suffice in the follow-up setting [70/85 (82.4%)
agreement]
An additional protocol suggestion to use gadoxetic acid–
enhanced MRI when finding an incidental lesion in a healthy
patient did not reach overall consensus (> 50% agreement)
and is not included among the consensus statements.
New sequences for dynamic imaging—current clinical
value
There are current limitations to dynamic contrast-enhanced
MRI of liver lesions, including (1) the requirement for an
AP and PVP that show an arterial phase–enhancing lesion
and washout compatible with HCC and (2) the need for spatial
resolution sufficient to detect 1–2-cm tumours combined with
temporal resolution sufficient to visualise contrast dynamics
within a single breath hold. Additional factors when using
gadoxetic acid are an injection rate 1 cc/s related to a smaller
injection volume and a lower total gadolinium dose (usually
0.025 mmol Gd/kg BW) compared with other ECCM, no
prior timing run, and concerns over respiratory motion-
related artefacts.
Solutions to these limitations are being developed. One solu-
tion is faster imaging, during a single breath hold, achieved by
(1) parallel imaging, through undersampling of the κ-space, and
use of receiver coils that provide spatial information to unwrap
the image [72]; and (2) view-sharing, utilising keyhole imaging
techniques, e.g. TRICKS (time-resolved imaging of contrast
kinetics) and TWIST (time-resolved angiography with stochas-
tic trajectories), to provide more frequent sampling of the centre
of the κ-space compared with the periphery. In one study using
gadoxetic acid, Pietryga et al used a high parallel acceleration
factor to perform multiple APs in one breath hold. The tech-
nique recoveredmost APs that would otherwise have been com-
promised by transient motion [73].
A second solution is to use a free-breathing approach.
Among multiple potential approaches, one is to acquire data
in a STAR VIBE (radial volumetric interpolated breath-hold
examination) sequence [74]. Fat-suppressed STAR VIBE is
acquired with stack-of-stars κ-space sampling, which uses
conventional sampling in the slice direction and radial sam-
pling in-plane. To speed up radial acquisition, compressed
sensing can be used, a method that exploits the compressibil-
ity or sparsity of MRI data to reconstruct under-sampled data.
This is the concept underlying the GRASP (golden-angle
radial sparse parallel) technique, which combines a golden-
angle ordering scheme, compressed-sensing reconstruction,
and parallel imaging.
The technique acquires continuous data over approximate-
ly 3–5 min in a radial fashion while the patient breathes nor-
mally. All required phases can then be reconstructed retro-
spectively, so that multiple APs and venous phases can be
obtained together. A study using this technique to extract per-
fusion parameters found—as expected—that total plasma
flow was reduced but additionally showed that the hepatocel-
lular uptake rate for gadoxetic acid was lower in cirrhotic
compared with that in non-cirrhotic liver [75].
XD-GRASP represents a further development in GRASP
imaging, utilising retrospective motion-resolved reconstruc-
tion for image acquisition, spanning from end-inspiration to
end-expiration, to acquire images. Chandarana et al reported
that free-breathing, motion-resolved XD-GRASP reconstruc-
tions provide high-quality multiphase images in patients un-
dergoing gadoxetic acid–enhanced liver MRI, superior in im-
age quality to standard GRASP reconstructions [76]. Other
techniques that enable rapid robust imaging are being investi-
gated and have the potential to help improve the image quality
of contrast-enhanced liver exams. Dedicated clinical studies
will be required to demonstrate the value of these novel
techniques.
Consensus statement 19 Conventional contrast-enhanced
multiphasic MRI remains limited with the need for (1) higher
spatial resolution (that more closely resembles CT) in the AP
aswell as higher temporal resolution to shorten the breath hold
and (2) greater robustness to eliminate/minimise motion-
related artefacts. [67/72 (93.1%) agreement]
Consensus statement 20 Recent advances in MRI that enable
fast imaging (advanced parallel imaging, view sharing, com-
pressed sensing) and more robust imaging (non-Cartesian
imaging) have the potential to improve multiphasic dynamic
liver imaging in patients undergoing gadoxetic acid–enhanced
liver MRI. However, more technical developments and defin-
itive clinical studies/trials are needed to demonstrate clinical
value. [67/68 (98.5%) agreement]
Summary
Gadoxetic acid–enhanced MRI has an important role in the
care of patients, offering a unique combination of sensitivity
and specificity that is recognised in recent management guide-
lines, and recommended over all other contrast agents and
imaging modalities in the Asian guidelines. Optimisation of
the acquisition techniques, timing, and other parameters of the
arterial, venous, and hepatobiliary phases is an area of ongo-
ing research to further enhance the utility of gadoxetic acid–
Eur Radiol (2020) 30:370–382378
enhanced MRI, while other research is exploring methods to
reduce associated artefacts and to utilise the latest advances in
multiphasic dynamic image acquisition.
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